Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

532 ARTÍCULOS , VIENDO DEL 181 AL 195

Microglial Cathepsin B and Porphyromonas gingivalis Gingipains as Potential Therapeutic Targets for Sporadic Alzheimer's Disease

Nakanishi H, Nonaka S, Wu Z.

CNS Neurol Disord Drug Targets. 2020;19(7):495-502. doi: 10.2174/1871527319666200708125130.

Invited Review - Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials

Boche D, Nicoll JAR.

Neuropathol Appl Neurobiol. 2020 Dec;46(7):623-640. doi: 10.1111/nan.12642. Epub 2020 Jul 25.

Hydroxychloroquine safety: A meta-analysis of randomized controlled trials

Eljaaly K, Alireza KH, Alshehri S, Al-Tawfiq JA.

Travel Med Infect Dis. 2020 Jul-Aug;36:101812. doi: 10.1016/j.tmaid.2020.101812. Epub 2020 Jul 6.

The Emerging Role of Nutraceuticals and Phytochemicals in the Prevention and Treatment of Alzheimer's Disease

Calfio C, Gonzalez A, Singh SK, Rojo LE, Maccioni RB.

J Alzheimers Dis. 2020;77(1):33-51. doi: 10.3233/JAD-200443.

Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing

Fang J, Pieper AA, Nussinov R, Lee G, Bekris L, Leverenz JB, Cummings J, Cheng F.

Med Res Rev. 2020 Nov;40(6):2386-2426. doi: 10.1002/med.21709. Epub 2020 Jul 13.

The Use of Antimicrobial and Antiviral Drugs in Alzheimer's Disease

Iqbal UH, Zeng E, Pasinetti GM.

Int J Mol Sci. 2020 Jul 12;21(14):4920. doi: 10.3390/ijms21144920.

Current Strategies and Novel Drug Approaches for Alzheimer Disease

Ghai R, Nagarajan K, Arora M, Grover P, Ali N, Kapoor G.

CNS Neurol Disord Drug Targets. 2020;19(9):676-690. doi: 10.2174/1871527319666200717091513.

Pathogenesis and promising therapeutics of Alzheimer disease through eIF2α pathway and correspondent kinases

Moradi Majd R, Mayeli M, Rahmani F.

Metab Brain Dis. 2020 Dec;35(8):1241-1250. doi: 10.1007/s11011-020-00600-8. Epub 2020 Jul 17.

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease

Plotkin SS, Cashman NR.

Neurobiol Dis. 2020 Oct;144:105010. doi: 10.1016/j.nbd.2020.105010. Epub 2020 Jul 16.

Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer's disease or should they be looking elsewhere?

Imbimbo BP, Ippati S, Watling M.

Expert Opin Drug Discov. 2020 Nov;15(11):1241-1251. doi: 10.1080/17460441.2020.1793755. Epub 2020 Jul 20.

Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials

Yu JT, Xu W, Tan CC, Andrieu S, Suckling J, Evangelou E, Pan A, Zhang C, Jia J, Feng L, Kua EH, Wang YJ, Wang HF, Tan MS, Li JQ, Hou XH, Wan Y, Tan L, Mok V, Tan L, Dong Q, Touchon J, Gauthier S, Aisen PS, Vellas B.

J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1201-1209. doi: 10.1136/jnnp-2019-321913. Epub 2020 Jul 20.

Brain cell somatic gene recombination and its phylogenetic foundations

Kaeser G, Chun J.

J Biol Chem. 2020 Sep 4;295(36):12786-12795. doi: 10.1074/jbc.REV120.009192. Epub 2020 Jul 22.

Brain angiotensin II and angiotensin IV receptors as potential Alzheimer's disease therapeutic targets

Royea J, Hamel E.

Geroscience. 2020 Oct;42(5):1237-1256. doi: 10.1007/s11357-020-00231-y. Epub 2020 Jul 22.

An evaluation on potential anti-inflammatory effects of β-lapachone

Mokarizadeh N, Karimi P, Kazemzadeh H, Fathi Maroufi N, Sadigh-Eteghad S, Nikanfar S, Rashtchizadeh N.

Int Immunopharmacol. 2020 Oct;87:106810. doi: 10.1016/j.intimp.2020.106810. Epub 2020 Jul 21.

Multitarget Therapeutic Strategies for Alzheimer's Disease: Review on Emerging Target Combinations

Maramai S, Benchekroun M, Gabr MT, Yahiaoui S.

Biomed Res Int. 2020 Jun 30;2020:5120230. doi: 10.1155/2020/5120230. eCollection 2020.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias